

*Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.*

**CanSino Biologics Inc.**

**康希諾生物股份公司**

*(A joint stock company incorporated in the People's Republic of China with limited liability)*

**(Stock code: 6185)**

**VOLUNTARY ANNOUNCEMENT  
ENROLLMENT OF PHASE III CLINICAL TRIAL FOR 13-VALENT  
PNEUMOCOCCAL POLYSACCHARIDE CONJUGATE VACCINE  
(CRM197, TT)**

This announcement is made by CanSino Biologics Inc. (the “**Company**”) on a voluntary basis.

The Company is pleased to announce that the Company has initiated the enrollment of a phase III clinical trial for the 13-Valent pneumococcal polysaccharide conjugate vaccine (CRM197, TT) (the “**PCV13i**”) developed by the Company. The Company has made improvements in the conjugate design and manufacturing processes of its PCV13i candidate based on its proprietary conjugate vaccine manufacturing know-how. The Company received the approval of clinical trial application for the PCV13i from the National Medical Products Administration of China in April 2019 and has completed the phase I clinical trial in 2020.

**Cautionary Statement required by Rule 18A.05 of the Rules Governing the Listing of Securities of The Stock Exchange of Hong Kong Limited:** We cannot guarantee that we will ultimately develop or commercialize PCV13i successfully. Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By Order of the Board  
**CanSino Biologics Inc.**  
**Xuefeng YU**  
*Chairman*

Hong Kong, April 13, 2021

*As at the date of this announcement, the board of directors comprises Dr. Xuefeng YU, Dr. Shou Bai CHAO, Dr. Tao ZHU and Dr. Dongxu QIU as executive directors, Mr. Qiang XU, Mr. Liang LIN, Ms. Nisa Bernice Wing-Yu LEUNG and Mr. Zhi XIAO as non-executive directors, and Mr. Shiu Kwan Danny WAI, Ms. Zhu XIN, Mr. Shuifa GUI and Mr. Jianzhong LIU as independent non-executive directors.*